Medical Oncology Department, Bakırkoy Sadi Konuk Training and Research Hospital, Bakırköy/Istanbul, Turkey.
J Oncol Pharm Pract. 2021 Jul;27(5):1106-1111. doi: 10.1177/1078155220949642. Epub 2020 Aug 16.
The response patterns of immune checkpoint inhibitors (ICIs) have been recognized to differ from those seen in standard cytotoxic and targeted therapy. Pseudoprogression and hyperprogression are new clinical phenomena specific to the field of immuno-oncology. In this study, we aimed to assess the frequency of hyperprogression and pseudoprogression in metastatic RCC and melanoma patients treated in our institution with the programmed cell death protein-1 inhibitor nivolumab.
The medical records of all metastatic melanoma and renal cell carcinoma patients that were treated with nivolumab (n = 54) in Bakirkoy Dr. Sadi Konuk Training and Research Hospital (Istanbul-Turkey), Medical Oncology Clinic between June 2017 and December 2019 were retrospectively analyzed.
Hyperprogression and pseudoprogression rates were 12% and 9%, respectively and that is consistent with published data.
Pseudoprogression and hyperprogression are new radiologic response patterns with immunotherapy agents. It is critical to be aware of these two phenomena in order to make the right decisions for patients.
免疫检查点抑制剂（ICI）的反应模式已被认为与标准细胞毒性和靶向治疗不同。假性进展和超进展是免疫肿瘤学领域特有的新临床现象。在这项研究中，我们旨在评估我们机构中接受程序性死亡蛋白-1 抑制剂纳武利尤单抗治疗的转移性肾细胞癌和黑色素瘤患者中出现超进展和假性进展的频率。
回顾性分析了 2017 年 6 月至 2019 年 12 月期间在 Bakirkoy Dr. Sadi Konuk 培训和研究医院（土耳其伊斯坦布尔）医学肿瘤学诊所接受纳武利尤单抗（n=54）治疗的所有转移性黑色素瘤和肾细胞癌患者的病历。
超进展和假性进展的发生率分别为 12%和 9%，与已发表的数据一致。
假性进展和超进展是免疫治疗药物的新的放射学反应模式。了解这两种现象对于为患者做出正确决策至关重要。
